<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lifemd Inc — News on 6ix</title>
<link>https://6ix.com/company/lifemd-inc</link>
<description>Latest news and press releases for Lifemd Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 12:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lifemd-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683590ea78dffbe2df1023c7.webp</url>
<title>Lifemd Inc</title>
<link>https://6ix.com/company/lifemd-inc</link>
</image>
<item>
<title>LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management</guid>
<pubDate>Fri, 10 Apr 2026 12:15:00 GMT</pubDate>
<description>LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatmen</description>
</item>
<item>
<title>LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-offers-novo-nordisks-industry-first-wegovyr-telehealth-subscription-program</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-offers-novo-nordisks-industry-first-wegovyr-telehealth-subscription-program</guid>
<pubDate>Tue, 31 Mar 2026 12:45:00 GMT</pubDate>
<description>Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo NordiskNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP</description>
</item>
<item>
<title>LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-appoints-veteran-healthcare-finance-executive-as-chief-financial-officer-and-expands-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-appoints-veteran-healthcare-finance-executive-as-chief-financial-officer-and-expands-leadership-team</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment</description>
</item>
<item>
<title>LifeMD Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-reports-fourth-quarter-and-full-year-2025-results-3</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-reports-fourth-quarter-and-full-year-2025-results-3</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.Fourth quarter revenue increased 4% to $46.9 million; adjusted</description>
</item>
<item>
<title>LifeMD to Participate in Two Investor Conferences During March</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-to-participate-in-two-investor-conferences-during-march</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-to-participate-in-two-investor-conferences-during-march</guid>
<pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
<description>NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside</description>
</item>
<item>
<title>LifeMD to Report Fourth Quarter 2025 Financial Results on March 9</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-to-report-fourth-quarter-2025-financial-results-on-march-9</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-to-report-fourth-quarter-2025-financial-results-on-march-9</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-5</description>
</item>
<item>
<title>LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-announces-closing-50-million-133000903</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-announces-closing-50-million-133000903</guid>
<pubDate>Tue, 06 Jan 2026 13:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no</description>
</item>
<item>
<title>LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-expands-collaboration-novo-nordisk-130500329</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-expands-collaboration-novo-nordisk-130500329</guid>
<pubDate>Mon, 05 Jan 2026 13:05:00 GMT</pubDate>
<description>Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment optionsNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehe</description>
</item>
<item>
<title>LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-declares-quarterly-dividend-series-130000548</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-declares-quarterly-dividend-series-130000548</guid>
<pubDate>Fri, 26 Dec 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD®</description>
</item>
<item>
<title>LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-recognized-2025-deloitte-technology-130000407</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-recognized-2025-deloitte-technology-130000407</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME’s America’s Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD’s continued revenue growth, financial stability, and emerging leadership position in the health technology sector. “Inclusion on these lists of North America’</description>
</item>
<item>
<title>LifeMD Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-reports-third-quarter-2025-210500768</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-reports-third-quarter-2025-210500768</guid>
<pubDate>Mon, 17 Nov 2025 21:05:00 GMT</pubDate>
<description>Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.Paid off all outstanding debt during the quarter.Subsequent to quarter end, fully divested our majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.Continued to diversify clinical platform with new launches in women’s health, men’s health an</description>
</item>
<item>
<title>LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-offer-market-leading-pricing-130000820</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-offer-market-leading-pricing-130000820</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality careNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $1</description>
</item>
<item>
<title>LifeMD to Participate in the BTIG Digital Health Forum</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-participate-btig-digital-health-130000328</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-participate-btig-digital-health-130000328</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by co</description>
</item>
<item>
<title>LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-reschedules-third-quarter-2025-221500124</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-reschedules-third-quarter-2025-221500124</guid>
<pubDate>Wed, 05 Nov 2025 22:15:00 GMT</pubDate>
<description>NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD’s third quarter 2025</description>
</item>
<item>
<title>LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-divests-majority-interest-worksimpli-141500930</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-divests-majority-interest-worksimpli-141500930</guid>
<pubDate>Tue, 04 Nov 2025 14:15:00 GMT</pubDate>
<description>Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy BusinessesNEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced the sale of its majority ownership interest in WorkSimpli Software LLC (“WorkSimpli”) in a transaction valuing WorkSimpli at an enterprise value of approximately $65 million. The buyer group was led</description>
</item>
<item>
<title>LifeMD to Report Third Quarter 2025 Financial Results on November 6</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-report-third-quarter-2025-120000176</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-report-third-quarter-2025-120000176</guid>
<pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on November 6, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-245-3047International Dia</description>
</item>
<item>
<title>LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women’s Health Program</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-names-dr-tara-scott-120000732</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-names-dr-tara-scott-120000732</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>Renowned Menopause and Hormone Specialist to Help Guide and Represent LifeMD’s Comprehensive and Personalized Care Offering for WomenNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “The Hormone Guru,” as ambassador and clinical advisor for its comprehensive women’s health program. A respected physician, educator, and advocate, Dr. Scott will help champi</description>
</item>
<item>
<title>Health-E Commerce® Expands Telehealth Weight Loss Options with MEDVi and Remedy Meds</title>
<link>https://6ix.com/company/lifemd-inc/news/health-e-commercer-expands-telehealth-weight-loss-options-with-medvi-and-remedy-meds</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/health-e-commercer-expands-telehealth-weight-loss-options-with-medvi-and-remedy-meds</guid>
<pubDate>Tue, 21 Oct 2025 14:36:00 GMT</pubDate>
<description>Health-E Commerce®, the parent brand to FSA Store® and HSA Store®, the first and leading online stores dedicated to selling only products and services that are considered eligible for flexible spending accounts (FSAs) and health savings accounts (HSAs), today announced that it has expanded the selection of trusted weight loss medications available to people who shop at FSA Store® and HSA Store®.</description>
</item>
<item>
<title>LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-offers-ozempic-499-per-120000947</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-offers-ozempic-499-per-120000947</guid>
<pubDate>Tue, 30 Sep 2025 12:00:00 GMT</pubDate>
<description>Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as wel</description>
</item>
<item>
<title>LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/lifemd-inc/news/lifemd-participate-roth-4th-annual-200600967</link>
<guid isPermaLink="true">https://6ix.com/company/lifemd-inc/news/lifemd-participate-roth-4th-annual-200600967</guid>
<pubDate>Thu, 25 Sep 2025 20:06:00 GMT</pubDate>
<description>NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day. Investors can register for the conference by contacting their ROTH Capital Partners representative. About LifeMD, Inc. LifeMD</description>
</item>
</channel>
</rss>